MP Biomedicals announces the launch of advanced gastrointestinal diseases diagnostic kits

FHS
August 27, 2024
11:17 am

MP Biomedicals completes its range of in vitro diagnostic tests for infectious diseases with new immunochromatographic-based qualitative rapid tests.The new diagnostic kits by MP Biomedicals leverage cutting-edge technology to deliver precise results, enabling healthcare professionals a rapid and accurate detection of Helicobacter pylori, Salmonella typhi and Vibrio cholerae serogroups O1 and O139.

A startup backed by Nobel winner David Baker takes an AI twist on antibodies

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 31, 2024

AWS Launches Generative AI Solution That Auto Generates Clinical Notes

What You Should Know: Amazon Web Services, Inc. (AWS) launches AWS HealthScribe, a new HIPAA-eligible service that empowers healthcare software providers to build clinical applications

July 27, 2023

Filament Health Announces Warrant Exercise and Note Conversion by Negev Capital and Concurrent Private Placement of Common Shares to Benjamin Lightburn, Chief Executive Officer | Psychedelic Invest

VANCOUVER, BC, June 3, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today

June 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.